Victor Sung, MD
Dr. Victor Sung, a native of Houston, TX, graduated from Vanderbilt University with a B.S. in Neuroscience and a minor in music in 2001. He received his medical degree from UT-Southwestern in Dallas in 2005. He completed residency training in neurology at the University of Alabama at Birmingham (UAB) in 2009, during which time he was elected to membership of the Alpha Omega Alpha Honor Society and received the Argus Award for Best Neurology Resident. He currently serves as Director of the UAB / HDSA Huntington’s Disease Center of Excellence, serving more than 200 HD patients across the southeast. The UAB COE was awarded the HDSA Excellence in Clinical Care Award in 2017. Dr. Sung was awarded the President’s Award for Excellence in Teaching in 2018. Dr. Sung has been honored to serve on the HDSA Board of Trustees since 2017.
Teresa’s grandmother began battling HD before Teresa’s birth and the disease continues to impact her family including losing her Dad in 1998. Her family started supporting HD families during the CCHD days. Teresa supports her local chapter as a committee member for the IL Walk for Hope and the IL Celebration of Hope. She participates on the Center Programs Education and Advisory Committee and the National Field Committee.
Teresa earned a Bachelor of Science in Psychology and an MBA in her educational pursuits. She works as an IT Project Manager for an agricultural and construction manufacturing company. Teresa along with her husband, Craig give back to HDSA and other charities to recognize their life contains more blessings than negatives.
E.J. is the grandmother of twin granddaughters who are at-risk of Huntington’s disease. The girls’ brother and her grandson, Matthew, died at age 6 from Juvenile HD in May 2008. Her son, Scott, died at age 44 from complications of HD in January 2015 as well as her former husband, Doug, also died from HD in 2002. A long-time resident of Southern California, E.J. moved to Olympia, WA with her husband, Art, to be close to her granddaughters and daughter-in-law.
E.J. has been active in HDSA since 2006. She served on the board of the HDSA-Orange County chapter from 2008 – 2013 and as Chapter President from 2010 – 2012. She was name HDSA-OC Volunteer of the Year in 2011 and was recognized as one of the top fundraisers of HDSA Team Hope Walk in 2013 and 2015. Currently sitting on the board and Team Hope Walk Coordinator for the Washington State Chapter.
After 40 years with Toyota Motor Sales, U.S.A., Inc. she retired from a career of various management positions including, administration, marketing, merchandising, and distribution/logistics. E.J. holds a Bachelors of Science degree from University of Redlands (CA).
In tribute to her son and grandson and in an effort to raise awareness and funds for the fight against HD, E.J. has embarked on several long-distance walks to raise awareness and fundraise. Some of the walks have been the 554 mile Camino de Santiago pilgrimage in August 2015 raising more than $16,000 for HDSA Team Hope Walk. Then in May 2019 she completed her next trek of walking to the 21 California Missions (approximately 800 miles) up the coast of California raising over $51,000 over a two year period. She will walk to the ends of the earth to raise awareness of Huntington’s disease and to raise funds for research, education and family services.
Kamran has over 15 years of experience in the biotechnology industry. Kamran held various finance, accounting and project management roles with increasing responsibility at Ovation Pharmaceuticals, Lundbeck, Fresenius Kabi, Naurex, AveXis, and Rocket Pharmaceuticals.
Kamran received his Bachelor of Business Administration degree from the Ross School of Business at University of Michigan and MBA in Finance from the Kelley School of Business at Indiana University.
Jenne Coler-Dark is gene positive for Huntington’s Disease and has two children at risk. She found out HD was in her family in 2014 and has been working to advocate for patients, and raise funds for HDSA ever since. In 2016, Jenne along with her family hosted the Freeze HD event in Los Angeles. She continues to participate in the HDSA annual Freeze HD event, along with other HD volunteer engagements with HDdenNoMore, and CHDI.
Jenne graduated from the University of San Francisco with a degree in International Business. She has worked for Experian for the last 13 years in a variety of roles from Professional Services, Account Management, and Program Management.
After living in the Bay Area for over a decade, Jenne and her family relocated back to Southern California to be closer to her mom and sisters.
Angela Allen has two children who are at risk of HD. The family was unaware of their at-risk status until her children’s grandmother became symptomatic and was diagnosed in the early 2000’s. Angela and her family found HDSA during this time as they sought help to learn how to support her children’s grandmother and their father who also died of HD in 2019. She finds HDSA invaluable as she and her children come to terms with what it means for them to be at risk.
Professionally, Angela Allen is an executive coach, leadership consultant and business advisor. She is passionate about helping leaders and organizations grow. She brings rich leadership and organizational development experience to her work having held executive roles in sales, human resources, operations and as interim CEO for several successful organizations in the human capital arena. Angela has a B.A. in Organizational Psychology from The University of Michigan and an MBA from Northwestern’s Kellogg School of Management. Serving on the HDSA Board of Trustees and giving back to this wonderful community is a top priority to Angela and her family.
Mr. Brennan is currently the CEO/President of Alentia Therapeutics, Inc. and the Business and Operations Advisor of NeuroTau, Inc. Both companies are early stage start-up pharmaceutical companies focused on medicines for Alzheimer’s Disease and other Neurodegenerative Diseases.
Dan has over 20 years of experience in the biotechnology and pharmaceutical industry, most recently as Chief Commercial Officer of Catalyst Pharmaceuticals and Chief Operating Officer for Edge Therapeutics. He was the VP/General Manager of Lundbeck Inc from 2009-2015 and led the team that launched Xenazine (tetrabenazine) as the first FDA approved treatment for chorea associated with Huntington’s Disease. He has also worked at Abbott Laboratories and Eli Lilly and Company working on business, strategy and product development for numerous central nervous system medicines and devices.
Dan started his working career in Social Work for abused and neglected inner-city children at a not-for-profit organization dedicated to care, treatment, education and advocacy for children in Chicago, IL. He has continued his non-profit volunteering over the years at Court Appointed Special Advocates for Children (CASA) in Indianapolis and Lake County, IL, Alzheimer’s Association of Central Indiana, Eli Lilly Credit Union, Jeuga Como Campeon, and now on the Board of Trustees at HDSA. He has attended numerous Hope Walks, HDSA fundraisers and Annual Conventions over the years. He is the married father of three teenage girls and enjoys running, swimming and biking.
Jeff Carroll, PhD
Dr. Jeff Carroll is an Associate Professor in the Behavioral Neuroscience Program and the Department of Psychology at Western Washington University. Dr. Carroll is CoFounder of HDBuzz.net and continues to serve as the site’s Editor-in-Chief. During his PhD he trained with Michael Hayden (University of British Columbia), his postdoctoral studies were conducted under the supervision of Marcy MacDonald (MGH, Harvard Medical School). As well as conducting research, Dr. Carroll is a member of an HD family and carries the mutation which causes HD.
Mr. Coe is the CEO of CTI Meeting Technology, a global provider of workflow and virtual meeting application software to the meeting & event industry he has worked at for 38 years. Having watched HD take an aunt and a cousin, he is grateful for the work of the HDSA and eager to lend a hand to the fight. Mark is married to Kristen Coe and is the father of four children.
Mrs. Coen joined Editas Medicine, the world’s leading gene editing company, as Vice President of Business Development in 2017. She has more than 20 years of experience in Corporate and Business Development in the life sciences industry and previously worked at both Genzyme and Sanofi. Stacy has been responsible for partnerships and business transactions in the fields of oncology, transplant, multiple sclerosis, and rare diseases.
Stacy has been involved with HDSA for more than 30 years. Prior to joining the Board of Trustees, Stacy served as Treasurer of HDSA’s Massachusetts Chapter and has participated in many fundraising events, as well as clinical trials in support of the HDSA mission.
She is a married mother of two and enjoys kayaking, running, and photography.
With a true passion for patients and dedication to connecting people in need to resources, services and people, Wendy has built her career in patient advocacy in many rare disease communities and oncology.
Wendy Erler is the Vice President of STAR and Patient Insights and Advocacy at Alexion Pharmaceuticals where she is responsible for building an enterprise holistic solution model to gather and incorporate patient insights throughout the drug development and commercialization processes. She leads the Global Patient Advocacy function and has responsibility the advocacy team. Previously, Ms. Erler was on the executive leadership team at Wave Life Sciences where she led Patient Advocacy and Commercial. During her tenure, she built both functions as the organization initiated three rare disease clinical trials and developed the commercialization strategy. Prior to Wave, Wendy held roles of increasing responsibility at Biogen Idec starting in field sales and advancing through the commercial organization before serving as the patient advocacy lead for several rare disease programs. In these roles she gained experience in Newborn Screening, public policy, HTA’s, and bringing the patient voice into all aspects of drug development.
Wendy graduated from Miami University and earned her MBA from St. Joseph’s University.
Erin Furr-Stimming, MD
Dr. Furr-Stimming is an Associate Professor in the Department of Neurology and the Department of Neurobiology and Anatomy at the University of Texas Health Science Center at Houston, McGovern Medical School. She is passionate about treating the underserved and as a result, she served as the Chief of Neurology at Lyndon Baines Johnson Hospital for seven years. She is the Founder and Director of the HD clinic at UTHealth, McGovern Medical School which has been designated as the Huntington’s Disease Society America (HDSA) Center of Excellence. She is an active member of the UTHealth Movement Disorders division, UT MOVE. She serves as the Neurology Clerkship Director and has received the Dean’s Excellence in Teaching award every year since 2009. She has received the Dupont Master Clinical Teaching Award and she is a member of the Academy of Master Educators and a McGovern Society leader. She continuously strives to enrich the educational experience of the students, residents and fellows. She is the Chair of the American Academy of Neurology Consortium of Neurology Clerkship Directors. She has been named a Super Doctor by Texas Monthly and a Top Doctor by Houstonia magazine for the past several years. She received her medical degree from The Chicago Medical School in 2003 and completed her post graduate training, including a neurology residency and Movement Disorders fellowship at The University of Texas Health Science Center at Houston, where she became an Assistant Professor of Neurology in 2007.
Dr. Furr-Stimming is actively engaged with the Parkinson’s and Huntington’s disease community. She is the Chair of the Medical Advisory Board for the Houston Area Parkinson’s Society and a member of local HDSA affiliate and frequently volunteers for both nonprofit organizations. She previously served as the President for the Texas Neurologic Society, the largest state neurologic society in the country. She is currently the Vice President of the Houston Neurologic Society and Chair of the Education Committee for the Texas Neurologic Society. Dr. Furr-Stimming is the PI of multiple HD clinical trials and collaborates closely with basic scientists at UTHealth, McGovern Medical School to enhance and optimize treatment for individuals living with Huntington’s disease.
Beth Hoffman, PhD
Dr. Beth Hoffman is the Founder and CEO at Origami Therapeutics, Inc. At Origami, Dr. Hoffman is leveraging lessons learned during 20 years of CNS drug discovery to create a novel, precision medicine approach to treating neurodegenerative diseases by “fixing broken proteins”. Dr. Hoffman served on the Board of Directors at HDSA’s San Diego Chapter and currently serves on the Scientific Advisory Board of the Tau Consortium. Dr. Hoffman received an AB in Molecular Biology from Wellesley College, a PhD in Cell Biology from the Johns Hopkins University and was Chief of the Molecular Pharmacology Unit at the National Institute of Mental Health in Bethesda, Maryland.
James Hughes is MGIC’s Executive Vice President of Sales and Business Development. He began his sales career in 1987 in Washington, D.C. as an Account Executive. After moving to California in 1998 as a Sales Manager, he was promoted to Managing Director in 2001 where managed the Pacific Region. He moved to Milwaukee in 2015 to assume his current role. He holds a BS in Finance from the Villanova School of Business.
Jay is personally at risk for HD and the disease has had a lasting impact on his family. Being as close as possible to the cure and providing assistance along the way was the driver for his involvement with this special organization.
Jonathan Klein, Esq.
Jonathan Klein is Chair of the Mergers and Acquisitions Group at DLA Piper in New York City. He concentrates his practice in the areas of mergers and acquisitions, private equity, corporate finance, securities matters and restructuring for both domestic and international clients.
Jonathan has represented public and private companies in negotiated domestic and cross border acquisitions and dispositions (including mergers, stock transactions, asset deals and divestitures), as well as bidders in contested transactions. Jonathan’s private equity experience includes domestic and international leveraged transactions for both financial and strategic parties. His corporate finance experience includes public and private offerings of equity and debt securities.
Jonathan’s general corporate practice includes advising public companies on SEC compliance and reporting issues, internal investigations, joint ventures, licensing and distribution agreements and providing general corporate advice and counsel to public and private companies, partnerships and individuals. He regularly counsels senior management, corporate boards and controlling stockholders with respect to acquisitions, dispositions, buyouts and general corporate and securities matters.
Jonathan has represented US and foreign clients in connection with cross-border acquisitions, divestitures, joint ventures, private financings, loan restructurings and workouts and general corporate matters.
Jonathan received his J.D. from Georgetown University Law Center where he graduated cum laude and his B.S. from Cornell University.
Ms. Dom Thomas joined Ochsner Health, as a Lead Medical Assistant in 2012 and currently works as Clinic Operations Manager for Our Community Health, partner site for Ochsner Health. Dom manages interdisciplinary clinics for Parkinson’s, Huntington’s, and Tourette’s Disease for adult and pediatric neurology patients. She also works closely with telemedicine team for acute management across the system for acute care areas.
Dom currently leads Ochsner’s Diversity and Inclusion Group ABLE (African Americans Building and Leading Equality) as Event Liaison Chair. She is also LEAN Yellow Belt Certified, IMPACT Certified Level 1 Training Instructor. She is also member of Phi Theta Kappa Honor Society and a Member of Phi Beta Chi Society.
Dom is very involved in community outreach focusing on underserved populations in the Greater New Orleans Area.
In Dom’s free time, she is a Zumba® Instructor and has been for the past 7 years. She has a high passion for fitness and bringing health and wellness to the movement disorder’s communities.
Leslie Thompson, PhD
Dr. Thompson is a world-renowned HD researcher and currently a professor at the University of California-Irvine School of Medicine.